Ordering
Available Variants1 kit
CHA.39298-1kit
Price
€546.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
1 kit | CHA.39298-1kit | €546.40 |
Professionally catalogued chemical listing prepared to support identification, technical review, safety visibility, and structured B2B sourcing workflows.
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| NACRES | NA.32 |
|---|---|
| UNSPSC Code | 12352108 |
| Storage temp. | 2-8°C |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| ppe | dust mask type N95 (US), Eyeshields, Gloves |
Technical Overview & Applications Use-case context
The Ampliflu Red easy to use Kit, with a CAS number of 119171-73-2, is a molecular diagnostic tool designed for the detection of influenza A and B viruses. This kit is characterized by its simplicity and ease of use, allowing for rapid and accurate diagnosis of influenza infections. The Ampliflu Red Kit utilizes a proprietary amplification technology to detect the genetic material of the influenza virus, providing sensitive and specific results. The kits streamlined protocol and user-friendly design make it an ideal solution for laboratories and healthcare facilities seeking to improve their influenza diagnostic capabilities. By leveraging the Ampliflu Red Kit, healthcare professionals can quickly and accurately diagnose influenza, enabling timely and effective treatment and management of the disease. This facilitates better patient outcomes and helps to mitigate the spread of influenza in the community.
